[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO900831L - Fremgangsmaate for fremstilling av piperidinforbindelser. - Google Patents

Fremgangsmaate for fremstilling av piperidinforbindelser.

Info

Publication number
NO900831L
NO900831L NO90900831A NO900831A NO900831L NO 900831 L NO900831 L NO 900831L NO 90900831 A NO90900831 A NO 90900831A NO 900831 A NO900831 A NO 900831A NO 900831 L NO900831 L NO 900831L
Authority
NO
Norway
Prior art keywords
piperide
compounds
procedure
preparation
alkynyl
Prior art date
Application number
NO90900831A
Other languages
English (en)
Other versions
NO900831D0 (no
Inventor
Per Sauerberg
Preben H Olesen
Charles H Mitch
Original Assignee
Ferrosan As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK82589A external-priority patent/DK82589A/da
Priority claimed from DK231589A external-priority patent/DK231589D0/da
Application filed by Ferrosan As filed Critical Ferrosan As
Publication of NO900831D0 publication Critical patent/NO900831D0/no
Publication of NO900831L publication Critical patent/NO900831L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Forbindelse med formel I. hvor Z er oxygen eller svovel,. R er H,_-alkyl,_-cykloalkyl,_-alkenyl eller C_-alkynyl,. og er uavhengig av hverandre calky1c-10alkeny1-10" alkynyl, C_-aikoxy, C_-cyklo-alkyl, Cj^_^Q-alkylamino,_io~ alkylaminomethyl, C_-alkoxymethyl, io, C_-alkoxyimino-methyl, halogen eller amino, eller et salt derav med en farmasøytisk aksep-tabel syre. Forbindelsene kan anvendes ved stimulering av ce kognitive funk-sjoner i forhjernen og hippocampus hos pattedyr, inkludert mennesker, og ved behandling avlzheimers sykdom.Fremstilling av forbindelsene er beskrevet.
NO90900831A 1989-02-22 1990-02-21 Fremgangsmaate for fremstilling av piperidinforbindelser. NO900831L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK82589A DK82589A (da) 1989-02-22 1989-02-22 Piperidinforbindelser, deres fremstilling og anvendelse
DK231589A DK231589D0 (da) 1989-05-12 1989-05-12 Piperidinforbindelser og deres fremstilling og anvendelse

Publications (2)

Publication Number Publication Date
NO900831D0 NO900831D0 (no) 1990-02-21
NO900831L true NO900831L (no) 1990-08-23

Family

ID=26064725

Family Applications (2)

Application Number Title Priority Date Filing Date
NO90900831A NO900831L (no) 1989-02-22 1990-02-21 Fremgangsmaate for fremstilling av piperidinforbindelser.
NO900830A NO179639C (no) 1989-02-22 1990-02-21 Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte piperidinforbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO900830A NO179639C (no) 1989-02-22 1990-02-21 Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte piperidinforbindelser

Country Status (22)

Country Link
US (5) US5043345A (no)
EP (2) EP0384285A3 (no)
JP (2) JPH02255680A (no)
KR (1) KR0163763B1 (no)
CN (1) CN1028105C (no)
AR (1) AR247565A1 (no)
AT (1) ATE123030T1 (no)
AU (2) AU4999690A (no)
CA (2) CA2010579A1 (no)
DE (1) DE69019550T2 (no)
DK (1) DK0384288T3 (no)
ES (1) ES2072323T3 (no)
FI (2) FI95704C (no)
GR (1) GR3017062T3 (no)
HU (2) HU221623B1 (no)
IE (1) IE69672B1 (no)
IL (2) IL93352A (no)
NO (2) NO900831L (no)
NZ (1) NZ232615A (no)
PH (1) PH26465A (no)
PT (2) PT93242A (no)
RU (1) RU2042676C1 (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372125A1 (en) * 1988-11-08 1990-06-13 Akzo N.V. Oxazole and thiazole derivatives
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
EP0459568A3 (en) * 1990-05-31 1992-09-30 Merck Sharp & Dohme Ltd. Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
USRE35822E (en) * 1990-08-21 1998-06-09 Novo Nordisk A/S Heterocyclic compounds
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5527813A (en) * 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
ATE164519T1 (de) * 1990-11-29 1998-04-15 Allergan Inc Verwendung von pyridine derivate zur behandlung der okulären hypertomie
EP0492903A1 (en) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5641791A (en) * 1991-08-13 1997-06-24 Novo Nordisk A.S Heterocyclic compounds and their preparation and use
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists
WO1993014089A1 (en) * 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5244906A (en) * 1992-01-23 1993-09-14 Dowelanco Insect control with substituted oxadiazole and thiadiazole compounds
US5631269A (en) * 1992-10-23 1997-05-20 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
HUT75038A (en) * 1993-06-04 1997-03-28 Novo Nordisk As Crystalline 3-(4-hexyloxi-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)l-hydrogentartartarate, process for it`s preparation and pharmaceutical composition comprising the same
HU221729B1 (hu) * 1993-08-19 2002-12-28 Novo Nordisk A/S Tiadiazolil-piridin-származékok alkalmazása antipszichotikus gyógyszerek előállítására
US5753683A (en) * 1993-08-19 1998-05-19 Novo Nordisk A/S Antipsychotic method
US5545638A (en) * 1993-12-21 1996-08-13 Novo Nordisk A/S Method of treating gastrointestinal motility disorders
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5672709A (en) * 1994-10-24 1997-09-30 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
AU4139096A (en) * 1994-10-31 1996-05-23 Eli Lilly And Company Method for treating anxiety
US5484794A (en) * 1994-11-09 1996-01-16 Eli Lilly And Company Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5612351A (en) * 1994-11-08 1997-03-18 Novo Nordisk A/S Method of treating urinary bladder dysfunctions
TW304167B (no) * 1995-01-30 1997-05-01 Lilly Co Eli
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation
US5763457A (en) 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US5998434A (en) * 1995-12-06 1999-12-07 Eli Lilly And Company Composition for treating pain
CA2239732A1 (en) * 1995-12-07 1997-06-12 Eli Lilly And Company Method for treating pain
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
WO1997039753A1 (en) * 1996-04-23 1997-10-30 Eli Lilly And Company Heterocyclic compounds
CA2250472A1 (en) * 1996-04-23 1997-10-30 Steven James Quimby Heterocyclic compounds
DE69724967D1 (de) * 1996-04-24 2003-10-23 Novo Nordisk As Heterozyklische verbindungen, ihre herstellung und ihre anwendung
US5767274A (en) * 1996-06-28 1998-06-16 Biomeasure, Incorporated Prenyl transferase inhibitors
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
ATE213413T1 (de) * 1996-08-01 2002-03-15 Lilly Co Eli Verwendung von 3-(4-hexyloxy-1,2,5-thiadiazol-3- yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) zur behandlung von bipolaren störungen
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
EP0934040A1 (en) * 1996-10-23 1999-08-11 Eli Lilly And Company Method for treating dementia due to aids
US6297262B1 (en) 1997-05-29 2001-10-02 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6211204B1 (en) 1999-01-22 2001-04-03 University Of Toledo Muscarinic receptor agonists
US6096767A (en) * 1999-01-22 2000-08-01 The University Of Toledo Muscarinic receptor agonists
US6376675B2 (en) 1999-01-22 2002-04-23 The University Of Toledo Muscarinic receptor agonists
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CN1821243B (zh) * 2005-08-30 2010-12-08 北京大学 取代的吡啶类m1受体激动剂、其制备方法及其用途
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101374836A (zh) * 2005-12-27 2009-02-25 托莱多大学 毒蕈碱激动剂及其使用方法
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20110294835A1 (en) 2008-05-15 2011-12-01 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3646870A1 (en) 2009-07-22 2020-05-06 Puretech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
NZ722077A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2996717A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX391629B (es) 2018-09-28 2025-03-21 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863B (zh) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
AU2023324882A1 (en) 2022-08-19 2025-03-20 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
US12269818B2 (en) 2023-04-24 2025-04-08 Terran Biosciences Inc. Analogs of xanomeline

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
IL83275A (en) * 1986-09-08 1994-02-27 Novo Nordisk As Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them
US5017618A (en) * 1987-03-16 1991-05-21 University Of Florida Labile derivatives of ketone analogs of 3-substituted-1-alkylamino-2-propanols and their use as beta-adrenergic blockers
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
DK162892C (da) * 1988-07-04 1992-05-11 Novo Nordisk As 1,2,5,6-tetrahydropyridinforbindelser, deres fremstilling og farmaceutiske praeparater indeholdende disse
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists

Also Published As

Publication number Publication date
EP0384288B1 (en) 1995-05-24
NO900830D0 (no) 1990-02-21
NO179639C (no) 1996-11-20
PT93241B (pt) 1996-01-31
PT93242A (pt) 1990-08-31
IL93423A0 (en) 1990-11-29
JPH02255680A (ja) 1990-10-16
DK0384288T3 (da) 1995-10-02
AU4999690A (en) 1990-08-30
US5284859A (en) 1994-02-08
HUT58326A (en) 1992-02-28
NZ232615A (en) 1992-06-25
US5712297A (en) 1998-01-27
FI900887A7 (fi) 1990-08-23
KR0163763B1 (ko) 1998-12-01
CA2010578A1 (en) 1990-08-22
CN1028105C (zh) 1995-04-05
FI900887A0 (fi) 1990-02-22
FI95704B (fi) 1995-11-30
JP2921578B2 (ja) 1999-07-19
HU211705A9 (en) 1995-12-28
US5559138A (en) 1996-09-24
CN1045104A (zh) 1990-09-05
IL93352A (en) 1994-08-26
FI900886A0 (fi) 1990-02-22
DE69019550T2 (de) 1995-10-05
EP0384288A2 (en) 1990-08-29
RU2042676C1 (ru) 1995-08-27
EP0384288A3 (en) 1991-04-10
PH26465A (en) 1992-07-27
JPH02255679A (ja) 1990-10-16
HU900884D0 (en) 1990-05-28
EP0384285A3 (en) 1991-04-24
IL93352A0 (en) 1990-11-29
FI95704C (fi) 1996-03-11
EP0384285A2 (en) 1990-08-29
AR247565A1 (es) 1995-01-31
GR3017062T3 (en) 1995-11-30
ATE123030T1 (de) 1995-06-15
AU629302B2 (en) 1992-10-01
US5041455A (en) 1991-08-20
HU221623B1 (hu) 2002-12-28
DE69019550D1 (de) 1995-06-29
IE69672B1 (en) 1996-10-02
NO179639B (no) 1996-08-12
KR910015569A (ko) 1991-09-30
AU4999790A (en) 1990-08-30
US5043345A (en) 1991-08-27
PT93241A (pt) 1990-08-31
NO900830L (no) 1990-08-23
NO900831D0 (no) 1990-02-21
CA2010579A1 (en) 1990-08-22
CA2010578C (en) 2000-05-23
IE900504L (en) 1990-08-22
ES2072323T3 (es) 1995-07-16

Similar Documents

Publication Publication Date Title
NO900831L (no) Fremgangsmaate for fremstilling av piperidinforbindelser.
NO171788C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fosfinsyrederivater
FI875681L (fi) Menetelmä farmaseuttisesti aktiivisten 4-(2,6,6-trimetyyli-sykloheks-1-enyl)-but-3-en-1-ynyylisubstituoitujen yhdisteiden valmistamiseksi
FI892603A7 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 4-(kinolin-2-yylimetoksi)fenyylietikkahappojohdannaisten valmistamiseksi
MX9306831A (es) Nuevos compuestos heterociclicos.
ES539446A0 (es) Un procedimiento para preparar un derivado de dihidropiridazinona
NO171853C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7beta-(2-(tiazol-4-yl)-2-alkoksyiminoacetamido)-3-((1-pyrazolio)metyl)-3-cefem-4-karboksylat-forbindelser
NO921281L (no) Piperidinderivater, fremgangsmaate for deres fremstilling og terapeutiske anvendelse
NO163568C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
NO161564C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-carbolin-3-oxadiazolylderivater.
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
NO850216L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte 5,11-dihydro-6-dibenz(b,e)-azepin-6-on-derivater
ES8307220A1 (es) "procedimiento para preparar derivados de dihidropiridina".
EP0270093A3 (en) Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties
ES2045067T3 (es) Procedimiento para preparar nuevos compuestos de tiazol.
ATE101040T1 (de) Derivate und analoge von pyrimidon zur behandlung von asthma und bestimmte hautkrankheiten.
NO842417L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylalkyl-(piperazinyl eller homopiperazinyl)-alkyl-(urinstoff eller tiourinstoff)-derivater
ES2016305B3 (es) Compuestos de piperazina, procedimiento para prepararlos y composicion farmaceutica y su uso.
DK148288A (da) N-phenethylaminoalkyl-benzamid-forbindelser, deres anvendelse til fremstilling af antiarrhythmia-laegemidler og farmaceutiske praeparater indeholdende forbindelserne
ES552782A0 (es) Un procedimiento para preparar un compuesto de n-fenil-trans-4-guanidincometilciclohexanocarboxamida.
IE811212L (en) Substituted phenoxy-aminopropanol derivatives
IT7967658A0 (it) 2 4 etil i pipera inil 4 fenilchinoline procedimento per la loro prepara ione e composizioni farmaceutiche contenenti tali composti
DE69212878D1 (de) Verwendung von Aminosteroiden zur Herstellung von pharmazeutischen Zubereitungen
AU1586588A (en) Fungicidal derivatives of propenoic acid and processes for their preparation
ES8601990A1 (es) Un procedimiento para preparar 2-arilimidazo (4,5-c) piridi-nas.